Physician profile
Louis Kuchnir
NPI 1043269731
$1,494.86
in general payments reported to CMS, 2019-2025
20 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $82.90 · 2021: $85.96 · 2022: $221 · 2023: $77.35 · 2024: $472 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.49 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $372.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $194.35 | 2019-2022 | |
| Ucb, INC. | $132.34 | 2025 | Bimzelx |
| Amgen INC. | $113.46 | 2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $93.14 | 2022-2024 | |
| Lilly USA, LLC | $77.44 | 2019 | |
| Smith+Nephew, INC. | $74.48 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $72.83 | 2019 | |
| Biofrontera INC. | $71.79 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $49.48 | 2022-2024 | |
| Leo Pharma INC. | $37.60 | 2021-2024 | Adbry |
| Genzyme Corporation | $32.94 | 2024 | |
| Arcutis Biotherapeutics, INC. | $28.77 | 2023 | |
| Janssen Biotech, INC. | $26.53 | 2024 | Tremfya |
| Krystal Biotech INC | $24.52 | 2023 | Vyjuvek |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $22.50 | 2024 | Hulio |
| Mimedx Group, INC. | $22.23 | 2024 | |
| Organon LLC | $19.80 | 2025 | Vtama |
| Kerecis Limited | $14.97 | 2022 | |
| Galderma Laboratories, L.P. | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Kuchnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.